Soleno Therapeutics SLNO 深 沪
等待开盘 05-12 09:30:00 美东时间
52.945
-0.005
-0.01%
华盛通- 最 高52.965
- 今 开52.96
- 成交量 50.85万股
- 最 低 52.90
- 昨 收 52.95
- 总市值 635.34万
- 52周最高 90.3199
- 市盈率 静 --
- 换手率 423.79%
- 52周最低 29.43
- 委 比 19.48%
- 总股本 0.00亿
- 历史最高 90.3199
- 量 比 0.54
- 振 幅 0.12%
- 历史最低 0.134
- 每 手 1
- 风险率 16.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wolfe Research Downgrades Soleno Therapeutics to Peer Perform
Wolfe Research analyst Kalpit Patel downgrades Soleno Therapeutics (NASDAQ:SLNO) from Outperform to Peer Perform.
04-07 21:40
Gold Edges Higher; ISM Services PMI Falls In March
US stocks rose on Monday, with the Dow up 0.2%. The ISM services PMI fell to 54 in March. European shares were mostly lower, while Asian markets closed higher.
04-07 00:29
Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market
Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
04-06 20:13
Neurocrine Biosciences Agrees To Acquire Soleno Therapeutics For $53/Share, With Equity Value Of $2.9B
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc. (NASDAQ:SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash,
04-06 19:07
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
04-06 18:40
'Neurocrine Nears $2.5bn-Plus Deal For Biotech Behind Obesity Disorder Treatment' - FT
https://www.ft.com/content/6642c09c-12df-4724-8ed4-a28c32b9b2b7?syn-25a6b1a6=1
04-06 16:21
Soleno Therapeutics Appoints Jennifer Fulk CFO, Succeeding James Mackaness
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial
02-26 21:03
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.
2025-12-12 02:17
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.
2025-11-11 23:22
Soleno Therapeutics Announces $100M Accelerated Share Repurchase Plan
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share
2025-11-11 20:01
